PAGE 2019 Meeting

11-14 June 2019
Stockholm, Sweden

  • Posters on visceral leishmaniasis and paediatric HIV

R&D Portfolio Update February 2019: DNDi Paediatric HIV programme

As development continues for a “4-in-1” fixed-dose combination (abacavir/lamivudine/ lopinavir/ritonavir) for young children, interim results of the LIVING study for an optimized “2-in-1” lopinavir/ritonavir paediatric formulation were released. The study – which enrolled over 1,000 children in sub-Saharan Africa – showed that 83% of children were virologically suppressed at 48 weeks, compared to 55% at the beginning of the study.

Inaugural DNDi training for health & science journalists in Kampala

In early October, 18 journalists from 11 African countries converged in Kampala, Uganda for DNDi’s first-ever training on health and science journalism. The three-day training was conducted during a week of workshops and meetings related to the work of DNDi and its many partners, culminating in the 11th DNDi Partners’ Meeting on 4 October 2018.

Paediatric HIV Stakeholders’ Meeting

3-4 October 2018
Kampala, Uganda

  • François Bompart, Director of Paediatric HIV/HCV Programmes, Isabelle Andrieux-Meyer, Head of Clinical Development Paediatric HIV/HCV Programmes, Jean-René Kiechel,Expert in R&D – panel discussion on DNDi‘s journey so far working on Paediatric HIV
  • Olawale Salami, Paediatric HIV Clinical Project Manager – panel discussion on access to child-adapted ARV formulations

22nd International AIDS Conference

23-27 July 2018
Amsterdam, the Netherlands

Side event on ending paediatric HIV, presentation on the LIVING study on paediatric HIV, two panel discussions, and poster discussion on TB/HIV co-treatment, and poster on caregiver adherence to oral lopinavir/ritonavir pellets to treat children.

Also: pre-conference workshop session on viral suppression in children taking oral LPV/r

PAGE 2018 Meeting

29 May-1 June 2018
Montreux, Switzerland
DNDi – poster presentation on TB/HIV paediatric co-treatment